Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYBB | P04839 | 6/20 | 1.00 |
| ▸ | NOX4 | Q9NPH5 | 6/20 | 1.00 |
| ▸ | NOX1 | Q9Y5S8 | 4/20 | 1.00 |
| ▸ | NOX3 | Q9HBY0 | 3/20 | 1.00 |
| ▸ | NOX5 | Q96PH1 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 3/20 | 0.77 |
| ▸ | MAPT | P10636 | 8/20 | 0.71 |
| ▸ | USP2 | O75604 | 7/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | XBP1 | P17861 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.69 |
| ▸ | GAA | P10253 | 2/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | SLC29A2 | Q14542 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17999762 | 1.00 | CYBB (1.00) | CYBBNOX4NOX1NOX3NOX5 | |
| SCHEMBL17999785 | 0.92 | CYBB (1.00) | CYBBNOX4NOX1NOX3NOX5 | |
| SCHEMBL17999847 | 0.89 | CYBB (1.00) | CYBBNOX4NOX1NOX3NOX5 | |
| SCHEMBL15662302 | 0.86 | MAPT (0.80) | CYBBNOX4NOX1NOX3NOX5 | |
| SCHEMBL15662479 | 0.84 | CYBB (1.00) | CYBBNOX4NOX1NOX3NOX5 | |
| SCHEMBL18029452 | 0.81 | CYBB (0.67) | CYBBNOX4NOX1NOX3NOX5 | |
| SCHEMBL21530421 | 0.81 | SMN1; SMN2 (1.00) | CYBBNOX4NOX1NOX3NOX5 | |
| SCHEMBL21530407 | 0.80 | MAPK1 (0.78) | CYBBNOX4NOX1NOX3NOX5 | |
| SCHEMBL21530475 | 0.80 | MAPT (0.85) | CYBBNOX4NOX1NOX3NOX5 | |
| SCHEMBL18542998 | 0.79 | MAPT (0.76) | CYBBNOX4NOX1NOX3NOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223560-A1 | NOX4 INHIBITOR COMPOSITIONS AND METHODS FOR REGENERATION OF DYSTROPHIC MUSCLE | Fulcrum Therapeutics, Inc. (US) | 2025-07-10 | — | — | US | claimed |
| WO-2024006796-A2 | NOX4 INHIBITOR COMPOSITIONS AND METHODS FOR REGENERATION OF DYSTROPHIC MUSCLE | Fulcrum Therapeutics, Inc. (US) | 2024-01-04 | — | — | WO | claimed |
| US-20230083417-A1 | THERAPEUTIC COMBINATION FOR THE TREATMENT OF BRAIN ISCHEMIA AND SAID THERAPEUTIC COMBINATION FOR USE IN THE TREATMENT OF BRAIN ISCHEMIA | UNIVERSITEIT MAASTRICHT (NL) | 2023-03-16 | — | — | US | claimed |
| EP-4110396-A1 | THERAPEUTIC COMBINATION FOR THE TREATMENT OF BRAIN ISCHEMIA AND SAID THERAPEUTIC COMBINATION FOR USE IN THE TREATMENT OF BRAIN ISCHEMIA | Universiteit Maastricht (NL) | 2023-01-04 | — | — | EP | claimed |
| US-20260041817-A1 | BIODEGRADABLE TISSUE REPLACEMENT IMPLANT AND ITS USE | THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4346928-B1 | BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST WEAKLY ADHERENT CELLS | US HEALTH (US) | 2026-01-14 | — | — | EP | disclosed |
| US-20250223560-A1 | NOX4 INHIBITOR COMPOSITIONS AND METHODS FOR REGENERATION OF DYSTROPHIC MUSCLE | Fulcrum Therapeutics, Inc. (US) | 2025-07-10 | — | — | US | disclosed |
| WO-2025049644-A1 | NOX4 INHIBITORS AND METHODS OF USING SAME | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2025-03-06 | — | — | WO | disclosed |
| WO-2025049640-A1 | MACROLIDE-NOX4 CONJUGATES AND USES THEREOF | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2025-03-06 | — | — | WO | disclosed |
| WO-2025049643-A1 | NOX4 INHIBITORS AND METHODS OF MAKING AND USING SAME | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20240271089-A1 | METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS | THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-08-15 | — | — | US | disclosed |
| US-20240261474-A1 | BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST WEAKLY ADHERENT CELLS | THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-08-08 | — | — | US | disclosed |
| EP-4346928-A1 | BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST WEAKLY ADHERENT CELLS | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4347795-A1 | METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-113226387-B | Biodegradable tissue replacement implants and uses thereof | 美国政府(由卫生和人类服务部的部长所代表) | 2024-02-23 | — | — | CN | disclosed |
| WO-2024006796-A2 | NOX4 INHIBITOR COMPOSITIONS AND METHODS FOR REGENERATION OF DYSTROPHIC MUSCLE | Fulcrum Therapeutics, Inc. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20230083417-A1 | THERAPEUTIC COMBINATION FOR THE TREATMENT OF BRAIN ISCHEMIA AND SAID THERAPEUTIC COMBINATION FOR USE IN THE TREATMENT OF BRAIN ISCHEMIA | UNIVERSITEIT MAASTRICHT (NL) | 2023-03-16 | — | — | US | disclosed |
| EP-4110396-A1 | THERAPEUTIC COMBINATION FOR THE TREATMENT OF BRAIN ISCHEMIA AND SAID THERAPEUTIC COMBINATION FOR USE IN THE TREATMENT OF BRAIN ISCHEMIA | Universiteit Maastricht (NL) | 2023-01-04 | — | — | EP | disclosed |
| WO-2022251477-A1 | BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST WEAKLY ADHERENT CELLS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-12-01 | — | — | WO | disclosed |
| WO-2022251499-A1 | METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250223560-A1 | NOX4 INHIBITOR COMPOSITIONS AND METHODS FOR REGENERATION OF DYSTROPHIC MUSCLE | NOX4, NOX1, NOX3 | CYBB 4/4885NOX4 1/4885NOX1 2/4885 |
| US-20260041817-A1 | BIODEGRADABLE TISSUE REPLACEMENT IMPLANT AND ITS USE | LGALS1, LGALS9, ALDH1A2 | CYBB 2393/4885NOX4 4055/4885NOX1 3859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.